Enzo Biochem reports 3rd-qtr and 9m results
New York, USA-based Enzo Biochem has reduced its loss both in the quarter and nine-month period ended April 30, 2008, according to an interim report, due to increased revenue from its Enzo Life Sciences division.
For the fiscal third quarter, the firm reported revenue of $18.9 million, up 36% versus the same period of the year before. Gross profit from operations was also up, rising 19% to $9.3 million. This brought the firm's net loss down to $2.1 million, or $0.06 per share, vs $3.8 million or $0.10 per share in the like period of 2007.
For the full nine months, the firm reported turnover of $56.6 million, up 62% on the same period ending in 2007. Gross profit from operations was $28.3 million, up 39%. This resulted in a total net loss of $7.4 million, or $0.20 per share, vs $9.9 million, or $0.29 per share.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze